Guided Therapeutics (GTHP) Other Non-Current Liabilities (2013 - 2025)
Guided Therapeutics (GTHP) reported Other Non-Current Liabilities of $37000.0 for Q4 2025, down 68.64% on a YoY basis from $118000.0 in Q4 2024, and down 53.16% sequentially from $79000.0 in Q3 2025.
Guided Therapeutics (GTHP) Other Non-Current Liabilities (2013 - 2025) Analysis & Trends
Guided Therapeutics (GTHP) has 12 years of Other Non-Current Liabilities data on file, last reported at $37000.0 in Q4 2025.
- For the quarter ending Q4 2025, Other Non-Current Liabilities fell 68.64% year-over-year to $37000.0; the trailing twelve-month figure through Dec 2025 stood at $37000.0 (down 68.64% YoY), and the FY2025 full-year result was $37000.0, down 68.64% from the prior year.
- Other Non-Current Liabilities retreated to $37000.0 in Q4 2025, from $79000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $118000.0 in Q4 2024 to a low of -$38000.0 in Q3 2021.
- A 4-year average of $29384.6 and a median of $29000.0 in 2021 frame the typical range for Other Non-Current Liabilities.
- Across the five-year window, Other Non-Current Liabilities slumped 205.56% in 2021 and surged 361.54% in 2025, its largest moves.
- Tracing GTHP's Other Non-Current Liabilities over 4 years: stood at $32000.0 in 2021, then tumbled by 115.62% to -$5000.0 in 2022, then soared by 2460.0% to $118000.0 in 2024, then tumbled by 68.64% to $37000.0 in 2025.
- Business Quant data shows GTHP's Other Non-Current Liabilities at $37000.0 in Q4 2025, $79000.0 in Q3 2025, and $60000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | Guided Therapeutics | 21.96 Mn | 21.89 Mn | 458,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 37,000.00 |
| Sep 30, 2025 | 79,000.00 |
| Jun 30, 2025 | 60,000.00 |
| Mar 31, 2025 | 66,000.00 |
| Dec 31, 2024 | 118,000.00 |
| Sep 30, 2024 | 20,000.00 |
| Jun 30, 2024 | 13,000.00 |
| Dec 31, 2022 | -5,000.00 |
| Sep 30, 2022 | -5,000.00 |
| Jun 30, 2022 | -24,000.00 |
| Dec 31, 2021 | 32,000.00 |
| Sep 30, 2021 | -38,000.00 |
| Jun 30, 2021 | 29,000.00 |
| Dec 31, 2020 | -32,000.00 |
| Sep 30, 2020 | 36,000.00 |
| Jun 30, 2020 | 7.58 Mn |
| Mar 31, 2020 | 1.80 Mn |
| Sep 30, 2019 | 6.10 Mn |
| Jun 30, 2019 | 6.48 Mn |
| Mar 31, 2019 | 4.32 Mn |